Main description:

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

Fiscal consequences of curing hepatitis C
mRNA vaccines and the race for a cure
Why the government does not deserve a piece of Biopharma's profits
Paying for drugs whose ultimate value is unknown
The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Contents:

Introduction

Chapter 1 The $1,000 Pill

Fiscal consequences of curing hepatitis C

Chapter 2 Enter the Payers

FDA approval does not guarantee high prices

Chapter 3 Pandemic

mRNA vaccines and the race for a cure

Chapter 4 Federal Investment in R&D

Why the government does not deserve a piece of Biopharma's profits

Chapter 5 Insulin

The true cost of a 100-year-old drug

Chapter 6 The $56,000 Alzheimer's Disease Drug

A questionable breakthrough

Chapter 7 Gene Therapies

How much is a life worth?

Chapter 8 Proving the Value of Expensive Drugs

Should we pay for drugs whose ultimate value is unknown?

Chapter 9 Generic Drugs

Built-in cost controls

Chapter 10 About Those Soaring Pharma Profits

Are they driving healthcare costs?

Chapter 11 Schemes to Lower Drug Prices

The impact of reduced revenues on R&D

Final Thoughts